Shares of Cara Therapeutics Inc. (NASDAQ:CARA) rose 9.7% during trading on Monday . The stock traded as high as $7.30 and last traded at $7.13, with a volume of 1,652,203 shares. The stock had previously closed at $6.50.

CARA has been the subject of several research analyst reports. Cantor Fitzgerald set a $24.00 price objective on shares of Cara Therapeutics and gave the stock a “buy” rating in a report on Thursday, September 15th. Stifel Nicolaus lowered their price objective on shares of Cara Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a report on Friday, August 5th. Zacks Investment Research downgraded shares of Cara Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, July 11th. Finally, Needham & Company LLC decreased their target price on shares of Cara Therapeutics from $27.00 to $23.00 and set a “buy” rating for the company in a research note on Sunday, August 7th. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. Cara Therapeutics has a consensus rating of “Buy” and an average price target of $20.56.

The firm’s market capitalization is $198.34 million. The firm’s 50-day moving average price is $5.96 and its 200 day moving average price is $5.85.

Cara Therapeutics (NASDAQ:CARA) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.42) by $0.06. The company had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.13 million. The company’s revenue was down 91.0% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.25) EPS. On average, analysts expect that Cara Therapeutics Inc. will post ($1.81) EPS for the current fiscal year.

A number of institutional investors have recently modified their holdings of CARA. Pictet Asset Management Ltd. increased its position in shares of Cara Therapeutics by 564.9% in the second quarter. Pictet Asset Management Ltd. now owns 775,898 shares of the biopharmaceutical company’s stock valued at $5,012,000 after buying an additional 659,198 shares during the last quarter. Opaleye Management Inc. boosted its stake in Cara Therapeutics by 100.2% in the first quarter. Opaleye Management Inc. now owns 855,000 shares of the biopharmaceutical company’s stock valued at $5,318,000 after buying an additional 428,000 shares during the period. JPMorgan Chase & Co. boosted its stake in Cara Therapeutics by 46.8% in the first quarter. JPMorgan Chase & Co. now owns 513,382 shares of the biopharmaceutical company’s stock valued at $3,194,000 after buying an additional 163,772 shares during the period. A.R.T. Advisors LLC boosted its stake in Cara Therapeutics by 798.6% in the first quarter. A.R.T. Advisors LLC now owns 139,303 shares of the biopharmaceutical company’s stock valued at $866,000 after buying an additional 123,800 shares during the period. Finally, Bridgeway Capital Management Inc. boosted its stake in Cara Therapeutics by 123.6% in the second quarter. Bridgeway Capital Management Inc. now owns 131,646 shares of the biopharmaceutical company’s stock valued at $633,000 after buying an additional 72,779 shares during the period. Institutional investors own 48.67% of the company’s stock.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Company is engaged in developing product candidates that focus on the body’s peripheral nervous system.

5 Day Chart for NASDAQ:CARA

Receive News & Ratings for Cara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.